stat-ins

By Aiden Flynn, Exploristics CEO

VUCA (Volatility, Uncertainty, Complexity and Ambiguity) is a term that is increasingly being used in areas of leadership, and strategic planning to capture the unpredictable nature of living and working …

By Aiden Flynn, Exploristics CEO

Drug developers running clinical trials face many challenges. However, a common pain point is recruitment. This can particularly bite when the studies involved are evaluating therapies for diseases where there are small populations or where …

By Kim Hacquoil, Exploristics CDSO

In our daily lives, we’re constantly faced with choices that impact our future. Some of these decisions may be relatively small, low impact ones like picking a restaurant for dinner or which film to watch. …

By Aiden Flynn, Exploristics CEO

I recently went to see an outstanding and thought-provoking play called Dr Semmelweiss in London’s West End.  It is a true story based on the life of Ignaz Philipp Semmelweis, a Hungarian obstetrician and scientist …

By Kimberley Hacquoil, Exploristics CDSO

Earlier this year, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) released a draft revision to their most widely recognised E6 guideline (ICH E6(R3)).  The overarching …

By Aiden Flynn, CEO at Exploristics

We are regularly approached by growing biotechnology companies for biostatistical support. Often, these companies either have no in-house statistical capability or only a single statistician. Understanding how best to support their needs got me …

By Kim Hacquoil, Exploristics CDSO

It is not possible for clinical trials to test investigational treatments on all potential patients. Therefore, clinical trials are conducted on a sample of participants drawn from the population of interest. The results of a …